CAMBRIDGE, Mass.–(BUSINESS WIRE)–InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced the publication of a manuscript in the peer-reviewed journal Spinal Cord describing its CONTEMPO registry study data. The CONTEMPO registry study, part of the Company’s IDE submission for the Neuro-Spinal Scaffold™, was designed to provide comprehensive natural history benchmarks for the Neuro-Spinal Scaffold™ clinical study results. The CONTEMPO study included neurological recovery data from three registries of spinal cord injury (SCI) patients with similar baseline characteristics to those in the INSPIRE 1.0 Study. The registries included the North American Clinical Trials Network (NACTN), European Multicenter Study about Spinal Cord Injury (EMSCI), and Spinal Cord Injury Model Systems. A total of 170 patients were included from the three registries, including 12 individuals from NACTN, 64 from EMSCI, and 94 from Model Systems. AIS conversion rates at approximately six months post-injury varied from 16.7% – 23.4% (21.1% weighted average) across the three registries.
Richard Toselli, M.D., InVivo’s President and Chief Executive Officer, said, “We are pleased to see the findings from the CONTEMPO registry study published in this peer-reviewed journal, and we are satisfied that the findings continue to support our understanding of the natural history of these acute SCI patients.”
The publication is now available electronically at: https://www.nature.com/articles/s41393-019-0299-8.